Ashwani Kumar

Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC

Abstract Purpose: Ret proto-oncogene (RET) fusions are highly heterogeneous oncogenic drivers occurring in approximately 1-2% of non-small cell lung cancer (NSCLC). While selpercatinib and pralsetinib have dramatically improved clinical outcomes of patients, acquired resistance i...